ライフサイエンスコーパス: farnesyl

1 was carried out in 9 steps from trans,trans-farnesyl acetate using a palladium catalyzed decarboxyla

2 epoxylinalool, (Z)-jasmone, 2-acetylpyrrole, farnesyl acetone, geranyl acetone, cadinol, cubenol and

3 imination of hydrogen diphosphate from (E,E)-farnesyl and dimethylallyl diphosphate (FDP and DMADP) t

4 ed for the DCS-catalyzed turnover of (2Z,6E)-farnesyl and neryl diphosphates, suggested the intermedi

5 4 of the catalytic domain in addition to the farnesyl and polybasic motifs.

6 in the active state, with membrane-anchored farnesyl and unrestrained HVR, the catalytic domain fluc

7 ent of Ras-PDEdelta inhibitors targeting the farnesyl binding pocket of PDEdelta with nanomolar affin

8 Furthermore, these data suggest that the farnesyl binding site in the exit groove may be signific

9 Mutational analysis of the potential farnesyl-binding sites on AIPL1 identified two critical

10 FBMN migration by disrupting the function of farnesyl biosynthetic enzymes.

11 In the first, the ( S)-epoxide of farnesyl bromide is transformed in just three steps to t

12 ofuran analogues were prepared from triepoxy farnesyl bromides by a zinc-initiated reduction-eliminat

13 on possible polycyclization pathways of the farnesyl cation leading to the complex sesquiterpene pen

14 After diphosphate expulsion, farnesyl cation reacts with the distal 10,11-double bond

15 erate possible carbocations derived from the farnesyl cation, the first reactive intermediate of the

16 hile-free method for the introduction of the farnesyl chain onto thiols.

17 ially the same positions as found in the two farnesyl chains in the substrates.

18 , and phosphorylated once more to generate a farnesyl-CoA amphiphile that self-assembles into spheric

19 cally transferring the farnesyl group of the farnesyl-CoA micelle onto a peptide via phosphopantethei

20 d C89R mutation prevented the binding of the farnesyl-Cys probe to AIPL1.

21 C-terminal membrane anchor that comprises a farnesyl-cysteine-methyl-ester and a polybasic domain.

22 and other cis-prenyl transferases (e.g. cis-farnesyl, decaprenyl, undecaprenyl diphosphate synthases

23 VPS35 bound to N-Ras in a farnesyl-dependent, but neither palmitoyl- nor guanosine

24 ion of the recombinant protein, SAV_76, with farnesyl diphosphate (1, FPP) in the presence of Mg(2+)

25 erea, catalyzes the multistep cyclization of farnesyl diphosphate (2) to the tricyclic sesquiterpene

26 color catalyzes the multistep cyclization of farnesyl diphosphate (2, FPP) to the tricyclic sesquiter

27 Incubation of (1R)-[1-(2)H]farnesyl diphosphate (2b) with recombinant presilphiperf

28 Cyclization of [13,13,13-(2)H(3)] farnesyl diphosphate (2d) gave [14,14,14-(2)H(3)]-3d, th

29 alogues of geranyl diphosphate (3-ClGPP) and farnesyl diphosphate (3-ClFPP), respectively.

30 Recombinant Mg25 converted farnesyl diphosphate (C(15)) predominantly to beta-cubeb

31 gh either geranyl diphosphate (C10) or trans-farnesyl diphosphate (C15), to yield monoterpenes and se

32 enzyme GGDP synthase (GGDPS) that condenses farnesyl diphosphate (FDP) and isopentenyl pyrophosphate

33 10-geranyl diphosphate (GDP) and only 4% C15-farnesyl diphosphate (FDP) in the presence of Co(2+) or

34 in order of increasing potency at inhibiting farnesyl diphosphate (FDP) synthase (their intracellular

35 zes the metal-dependent cyclization of (E,E)-farnesyl diphosphate (FDP) to the cadinane sesquiterpene

36 idago canadensis catalyzes the conversion of farnesyl diphosphate (FDP) to the plant sesquiterpene (+

37 products from its natural substrate (2E,6E)-farnesyl diphosphate (FDP).

38 Certain farnesyl diphosphate (FPP) analogs are potent inhibitors

39 Farnesyl diphosphate (FPP) analogues have proven to be b

40 trates for modification with the isoprenoids farnesyl diphosphate (FPP) and anilinogeranyl diphosphat

41 The polyisoprenoid diphosphates farnesyl diphosphate (FPP) and geranylgeranyl diphosphat

42 Farnesyl diphosphate (FPP) and geranylgeranyl diphosphat

43 ly synthesizes the "regular" sesquiterpenoid farnesyl diphosphate (FPP) by coupling isopentenyl dipho

44 ous or monitor pyrophosphate release and not farnesyl diphosphate (FPP) creation.

45 tep in its biosynthesis, condensation of two farnesyl diphosphate (FPP) molecules to dehydrosqualene,

46 transfer of a 15-carbon farnesyl group from farnesyl diphosphate (FPP) to a conserved cysteine in th

47 an initial condensation of two molecules of farnesyl diphosphate (FPP) to form presqualene diphospha

48 yzes the ionization-dependent cyclization of farnesyl diphosphate (FPP) to form the bicyclic eremophi

49 talyzes the condensation of two molecules of farnesyl diphosphate (FPP) to give presqualene diphospha

50 Transfer of the farnesyl group from farnesyl diphosphate (FPP) to proteins is catalyzed by p

51 The universal sesquiterpene precursor, farnesyl diphosphate (FPP), is cyclized in an Mg(2+)-dep

52 -carbon geranyl diphosphate (GPP), 15-carbon farnesyl diphosphate (FPP), or 20-carbon geranylgeranyl

53 atom from the alpha- and beta-phosphates of farnesyl diphosphate (FPP).

54 and a sesquiterpene, nerolidol, derived from farnesyl diphosphate (FPP).

55 sphates were good alternative substrates for farnesyl diphosphate (FPP).

56 sphate (GPP) and between IPP and GPP to give farnesyl diphosphate (FPP).

57 Toxoplasma gondii possesses a bifunctional farnesyl diphosphate (FPP)/geranylgeranyl diphosphate (G

58 substrates neryl diphosphate (NPP) and 2Z,6Z-farnesyl diphosphate (Z,Z-FPP).

59 beetle protein extracts, but only when (Z,E)-farnesyl diphosphate [(Z,E)-FPP] was offered as a substr

60 yme active site, we conclude that folding of farnesyl diphosphate alone does not always dictate the s

61 Here, the synthesis of a benzophenone-based farnesyl diphosphate analogue containing a stable phosph

62 Farnesyl diphosphate analogues with fluorine at C2 and C

63 Eleven farnesyl diphosphate analogues, which contained omega-az

64 The assays use [(3)H]farnesyl diphosphate and [(3)H]geranylgeranyl diphosphat

65 isoprenoid mevalonate pathway-intermediates, farnesyl diphosphate and geranylgeranyl diphosphate, als

66 functional, catalyzing the formation of both farnesyl diphosphate and geranylgeranyl diphosphate.

67 anisms, is subject to feedback regulation by farnesyl diphosphate and related compounds.

68 useful for identifying enzymes that utilize farnesyl diphosphate as a substrate.

69 The use of (2Z,6E)-farnesyl diphosphate as an alternate substrate for recom

70 picture of the conformation of enzyme-bound farnesyl diphosphate at the active site of presilphiperf

71 o be involved in isopentenyl diphosphate and farnesyl diphosphate biosynthesis leading to AN were not

72 essarily reflect the original orientation of farnesyl diphosphate bound in the corresponding enzyme a

73 osphate bound and with the product mimic E,E-farnesyl diphosphate bound.

74 ation of isopentenyl diphosphate (IPP), with farnesyl diphosphate catalysed by a cis-isoprenyltransfe

75 ogenes lacking conserved motifs required for farnesyl diphosphate cyclase activity.

76 r elongation factor, interacts directly with farnesyl diphosphate during rubber biosynthesis.

77 ed with the SNP rs2645424 on chromosome 8 in farnesyl diphosphate farnesyl transferase 1 (FDFT1) (P =

78 emethylase (CYP51A1), and squalene synthase (farnesyl diphosphate farnesyl transferase 1)) via novel

79 te synthase (FPS) catalyzes the synthesis of farnesyl diphosphate from isopentenyl diphosphate and di

80 n adds a further seven isoprene units to E,Z-farnesyl diphosphate in a processive manner to generate

81 ne cyclase that catalyzes the cyclization of farnesyl diphosphate in the first committed step of the

82 ta-caryophyllene and alpha-humulene from E,E-farnesyl diphosphate in trichomes of leaf but not of ste

83 f the tomato sesquiterpene synthases use z,z-farnesyl diphosphate in vitro as well, or more efficient

84 TCs from Dictyostelium discoideum converted farnesyl diphosphate into (2S,3R,6S,9S)-(-)-protoillud-7

85 hese results established that cyclization of farnesyl diphosphate involves displacement of the diphos

86 may be significantly more selective for the farnesyl diphosphate substrate than the active site bind

87 o as well, or more efficiently than, the e,e-farnesyl diphosphate substrate.

88 eactions, chimeric proteins constructed from farnesyl diphosphate synthase (chain elongation) and chr

89 Farnesyl diphosphate synthase (FDPS) catalyzes the conve

90 stimulate Vgamma2Vdelta2 cells by inhibiting farnesyl diphosphate synthase (FDPS) in the mevalonate p

91 y unrecognized beta2AR regulators, including farnesyl diphosphate synthase (FDPS).

92 nts of the first two enzymes in the pathway, farnesyl diphosphate synthase (FDS) and carotenoid synth

93 The amino acid sequences of farnesyl diphosphate synthase (FPPase) and chrysanthemyl

94 esized and evaluated as substrates for avian farnesyl diphosphate synthase (FPPase).

95 r therapeutic agents involving inhibition of farnesyl diphosphate synthase (FPPS) and geranylgeranyl

96 s modulated by the lipid biosynthesis enzyme farnesyl diphosphate synthase (FPPS).

97 r possible binding to the allosteric site in farnesyl diphosphate synthase (FPPS).

98 Farnesyl diphosphate synthase (FPS) catalyzes the synthe

99 related Z-prenyl diphosphate synthases, E,Z-farnesyl diphosphate synthase (Rv1086) and decaprenyl di

100 n at the low nanomolar level of the T. cruzi farnesyl diphosphate synthase (TcFPPS).

101 neryl diphosphate synthase1 (NDPS1) and Z,Z-farnesyl diphosphate synthase (zFPS), which are encoded

102 y by the targeted overexpression of an avian farnesyl diphosphate synthase along with two versions of

103 Farnesyl diphosphate synthase catalyzes the sequential c

104 We screened 26 bisphosphonates against a farnesyl diphosphate synthase from Plasmodium vivax, fin

105 ncer cells to pitavastatin is potentiated by farnesyl diphosphate synthase inhibitors or geranylgeran

106 re excellent competitive inhibitors of avian farnesyl diphosphate synthase with KI = 1.0 +/- 0.12 muM

107 res of one sulfonium bisphosphonate bound to farnesyl diphosphate synthase, finding that it binds exc

108 3-hydroxy-3-methylglutaryl-CoA reductase or farnesyl diphosphate synthase, reduced endometrial organ

109 ar to the isoprenoid chain elongation enzyme farnesyl diphosphate synthase, which also contains two a

110 similar in some respects to that of dimeric farnesyl diphosphate synthase, which is not a cyclase.

111 (nBPs) are bone-specific agents that inhibit farnesyl diphosphate synthase.

112 IP and DMAP can also competitively inhibit farnesyl diphosphate synthase.

113 synthesize long-chain trans-polyisoprene via farnesyl diphosphate synthases (FPSs).

114 zes the conversion of two molecules of (E,E)-farnesyl diphosphate to squalene via the cyclopropylcarb

115 e synthase that catalyzes the cyclization of farnesyl diphosphate to the novel tricyclic hydrocarbon,

116 step in HA biosynthesis is the conversion of farnesyl diphosphate to trichodiene (TD), a volatile org

117 , whereas VoTPS1 catalyzes the conversion of farnesyl diphosphate to valerena-1,10-diene.

118 ations of isotopically pure [2-(2)H(1)](E,E)-farnesyl diphosphate with recombinant patchoulol synthas

119 Incubation of farnesyl diphosphate with recombinant yeast squalene syn

120 phate, generating the 15-carbon product (E,Z-farnesyl diphosphate).

121 diphosphate and dimethylallyl diphosphate to farnesyl diphosphate, a crucial metabolic intermediate i

122 e synthase (FPPS) catalyzes the synthesis of farnesyl diphosphate, an important precursor of sterols,

123 was inactive, whereas the LSU produced GPP, farnesyl diphosphate, and geranylgeranyl diphosphate (GG

124 l cation, the product of 11,1-cyclization of farnesyl diphosphate, is the product of the first commit

125 ion that following the initial ionization of farnesyl diphosphate, minimal enzymatic intervention may

126 noterpene synthases and three that preferred farnesyl diphosphate, the substrate for sesquiterpene sy

127 on of the universal sesquiterpene precursor, farnesyl diphosphate, to form the bicyclic hydrocarbon a

128 scherichia coli, and demonstrated to cyclize farnesyl diphosphate, yielding beta-selinene as the domi

129 fuels and the rapid engineering of microbial farnesyl diphosphate-overproducing platforms for the pro

130 phate substrates neryl diphosphate and 2z,6z-farnesyl diphosphate.

131 ion mixtures of L-tryptophan with geranyl or farnesyl diphosphate.

132 lly phosphorylated to farnesyl phosphate and farnesyl diphosphate.

133 as altered templates for the cyclization of farnesyl diphosphate.

134 he total hydrocarbons obtained using (2E,6E)-farnesyl diphosphate.

135 g to the synthesis of farnesene isomers from farnesyl diphosphate.

136 out a gene for biosynthesis of the precursor farnesyl diphosphate.

137 squiterpene synthases, exclusively using Z-Z-farnesyl-diphosphate (zFPP) in plastids, probably arisen

138 ll interfering RNA showed that inhibition of farnesyl-diphosphate farnesyl transferase (squalene synt

139 Farnesyl-diphosphate synthase (FPPS) catalyzes the synth

140 nd characterization of two Toxoplasma gondii farnesyl-diphosphate synthase (TgFPPS) homologs.

141 In summary, we report the first bifunctional farnesyl-diphosphate/geranylgeranyl-diphosphate synthase

142 We characterized a farnesyl-electrostatic switch whereby protein kinase C p

143 the opposite preference of tH palmitoyls and farnesyl for ordered and disordered membrane domains, cl

144 To determine whether protein prenylation (farnesyl/geranylgeranylation) regulates matrix metallopr

145 reaction requires farnesyldiphosphate as the farnesyl group donor and is catalyzed by the farnesyltra

146 se (FTase) catalyzes transfer of a 15-carbon farnesyl group from farnesyl diphosphate (FPP) to a cons

147 Transfer of the farnesyl group from farnesyl diphosphate (FPP) to protei

148 on of geranyl diphosphate (GPP) with the cis-farnesyl group in phosphoglycolipid 5 to form the (C25)

149 The farnesyl group in the computed intermediate state assume

150 cs simulations collectively suggest that the farnesyl group is sequestered within a hydrophobic regio

151 Farnesylation, the attachment of a 15-carbon farnesyl group near the C-terminus of protein substrates

152 s achieved by enzymatically transferring the farnesyl group of the farnesyl-CoA micelle onto a peptid

153 whereas the rigid microdomains restrict the farnesyl group penetration.

154 The farnesyl group spontaneously inserts into the disordered

155 peptide pheromone conjugated to a C-terminal farnesyl group that makes it very hydrophobic.

156 FTase catalyzes the transfer of a farnesyl group to a conserved cysteine residue (Cys1p) o

157 The docking of the farnesyl group to the hydrophobic pockets located at bot

158 In some cases the farnesyl group was apparently split off from the peptide

159 s protein is permanently modified by a lipid farnesyl group, and acts as a dominant negative, disrupt

160 normal cleavage site to remove a C-terminal farnesyl group.

161 hich Gt can anchor through its myristoyl and farnesyl groups.

162 hat the GDP/GTP exchange, HVR sequestration, farnesyl insertion, and orientation/localization of the

163 AIPL1, deletion of which also abolished the farnesyl interaction.

164 y contribution of the two palmitates and the farnesyl is additive, was not known.

165 ur results suggest that the binding of PDE6A farnesyl is essential to normal function of AIPL1 and it

166 d their prenylation with a geranylgeranyl or farnesyl isoprenoid moiety and subsequent trafficking to

167 rate for posttranslational modification by a farnesyl isoprenoid.

168 N-acetyl-S-farnesyl-L-cysteine (AFC), a modulator of G protein and

169 Progerin retains a farnesyl lipid anchor at its carboxyl terminus, a modifi

170 We propose that the farnesyl lipid binds to a site at the opening of two tra

171 inhibitor (FTI), suggesting that progerin's farnesyl lipid is important for disease pathogenesis and

172 Whether RD is caused by the retention of farnesyl lipid on prelamin A, or by the retention of the

173 se (FTase) catalyzes transfer of a 15 carbon farnesyl lipid to cysteine in the C-terminal Ca1a2X sequ

174 phorylation of Ser-181 prohibits spontaneous farnesyl membrane insertion.

175 fic HVR binding to anionic phospholipids but farnesyl membrane orientation.

176 Ras isoforms, K-Ras4B HVR contains a single farnesyl modification and positively charged polylysine

177 as4B is targeted to the plasma membrane by a farnesyl modification that operates in conjunction with

178 trifluoromethoxy-AGPP gave both analogue and farnesyl modified dansyl-GCVIM but only farnesylated dan

179 Lipid anchors composed of palmitoyl and farnesyl moieties in H-, N-, and K-Ras are widely suspec

180 rminus of Rnd3 consisting of both the Cys241-farnesyl moiety and a Rho-associated coiled coil contain

181 The combined action of a farnesyl moiety and zinc finger-like region enable Type

182 subunit through direct interaction with the farnesyl moiety, mutations compromising the integrity of

183 witch by modulating the accessibility of its farnesyl moiety, which does not require any supportive p

184 groove in 14-3-3 proteins accommodating the farnesyl moiety.

185 spectra often revealed a neutral loss of the farnesyl moiety.

186 the hypothesis that AIPL1 directly binds the farnesyl moiety.

187 direct the attachment of either a 15-carbon farnesyl or a 20-carbon geranylgeranyl moiety in vitro.

188 Isoprenoids (i.e., farnesyl or geranylgeranyl groups) are attached to cyste

189 enyltransferase-catalyzed addition of either farnesyl or geranylgeranyl isoprenoid lipids, Rce1-catal

190 oteins resulting in the addition of either a farnesyl or geranylgeranyl isoprenyl lipid moiety to the

191 The modification of proteins with farnesyl or geranylgeranyl lipids, a process called prot

192 enerated in a three-step sequence in which a farnesyl-pantetheine conjugate is phosphorylated, adenyl

193 ntrations, is sequentially phosphorylated to farnesyl phosphate and farnesyl diphosphate.

194 Farnesol and farnesyl phosphate kinases have also been reported in pl

195 agonists is alkyl glycerol phosphate > LPA > farnesyl phosphates >> N-arachidonoylglycine.

196 lysine-POPG salt bridges and by nonspecific farnesyl-phospholipid van der Waals interactions.

197 synthesis of an internally truncated form of farnesyl-prelamin A (progerin).

198 dings indicate that progerin and full-length farnesyl-prelamin A are toxic to neurons of the enteric

199 TE24, nor does it lead to an accumulation of farnesyl-prelamin A in cells.

200 cally modified mice that express full-length farnesyl-prelamin A in neurons (Zmpste24-deficient mice

201 The accumulation of farnesyl-prelamin A in response to HIV-PI treatment was

202 ibit ZMPSTE24, leading to an accumulation of farnesyl-prelamin A.

203 Farnesyl protein transferase (FTase) or geranylgeranyl p

204 S, to date, successes of therapies targeting farnesyl protein transferase are modest.

205 vitro screen for resistance to lonafarnib, a farnesyl protein transferase inhibitor that blocks preny

206 on of imatinib and lonafarnib, we identified farnesyl protein transferase mutations in residues ident

207 we demonstrate that an inhibitor of p21(ras) farnesyl protein transferase suppressed the expression o

208 almitoyl), RhoA (geranylgeranyl), and K-Ras (farnesyl) proteins in different cell types.

209 We speculate that the resulting farnesyl protrusion toward the cell interior allows olig

210 urs) in the absence (control) or presence of farnesyl pyrophosphate (10 muM) or geranylgeranyl pyroph

211 he synthesis of the wound-healing inhibitors farnesyl pyrophosphate (FPP) and cortisol, ligands for t

212 by depleting mevalonate pathway metabolites farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophos

213 hese events were significantly attenuated by farnesyl pyrophosphate (FPP) but not by geranylgeranyl p

214 of the 15-carbon sterol pathway intermediate farnesyl pyrophosphate (FPP) cause increased Hmg2p ubiqu

215 ructure of inhibitor 1a co-crystallized with farnesyl pyrophosphate (FPP) in the active site of rat F

216 We apply this approach to regulate farnesyl pyrophosphate (FPP) production in the isoprenoi

217 roposed for the carbocationic cyclization of farnesyl pyrophosphate (FPP) to (+)-aristolochene cataly

218 ules of isopentenyl pyrophosphate (IPP) with farnesyl pyrophosphate (FPP) to generate the C(55) undec

219 Farnesyl pyrophosphate (FPP), a key intermediate in the

220 MEV, squalene and ergosterol, as well as the farnesyl pyrophosphate (FPP)-derived side products farne

221 yzes the biosynthesis of the C-15 isoprenoid farnesyl pyrophosphate (FPP).

222 e inhibitor GGTI-298, and prenyl substrates (farnesyl pyrophosphate [FPP] and geranylgeranyl pyrophos

223 tidic acid receptor with weaker responses to farnesyl pyrophosphate and geranylgeranyl diphosphate.

224 gly, the levels of the cholesterol precursor farnesyl pyrophosphate and its derivative geranylgeranyl

225 ived from dimethylorsellinic acid (DMOA) and farnesyl pyrophosphate have attracted much biosynthetic

226 from 3,5-dimethylorsellinic acid (DMOA) and farnesyl pyrophosphate have not been reported despite he

227 derived from geranylgeranyl pyrophosphate or farnesyl pyrophosphate is an essential requisite for cel

228 umoral effects through the modulation of the farnesyl pyrophosphate synthase (FPPS) activity.

229 that decreases bone resorption by inhibiting farnesyl pyrophosphate synthase (FPPS) in osteoclasts, p

230 he 5 alpha-halo-analogues potently inhibited farnesyl pyrophosphate synthase (FPPS) with IC50 values

231 its most firmly established cellular target, farnesyl pyrophosphate synthase (FPPS).

232 Human farnesyl pyrophosphate synthase (hFPPS) controls intrace

233 Human farnesyl pyrophosphate synthase (hFPPS) controls the pos

234 Human farnesyl pyrophosphate synthase (hFPPS) is the gate-keep

235 The human farnesyl pyrophosphate synthase (hFPPS), a key regulator

236 nthesis are catalyzed by the related enzymes farnesyl pyrophosphate synthase and geranylgeranyl pyrop

237 nomenon strongly augmented by zoledronate, a farnesyl pyrophosphate synthase inhibitor that increases

238 ntaining bisphosphonate zoledronate inhibits farnesyl pyrophosphate synthase, a key enzyme of the mev

239 droxy-3-methylglutaryl coenzyme A reductase, farnesyl pyrophosphate synthase, and cytochrome P-450-51

240 any, IPP and expressed much lower levels of farnesyl pyrophosphate synthase.

241 e gene encoding a phosphatase which converts farnesyl pyrophosphate to farnesol.

242 carboxamide ribotide (ZMP), GDP-mannose, and farnesyl pyrophosphate were found to be rapidly altered

243 Statins block production of farnesyl pyrophosphate, an intermediate in the synthesis

244 y hydroxymethylglutaryl-CoA, mevalonate, and farnesyl pyrophosphate, but not cholesterol and ubiquino

245 e isoprenoid biosynthetic pathway leading to farnesyl pyrophosphate, the immediate molecular precurso

246 e or geranylgeranyl pyrophosphate but not by farnesyl pyrophosphate.

247 formed both caryophyllene and humulene from farnesyl pyrophosphate.

248 es, such as geranylgeranyl pyrophosphate and farnesyl pyrophosphate.

249 VA), geranylgeranyl-pyrophosphate (GGPP) and farnesyl-pyrophosphate (FPP), all intermediates in the c

250 odel of MS are via depletion of isoprenoids (farnesyl-pyrophosphate and geranylgeranyl-pyrophosphate)

251 ygeranyl-pyrophosphate is more critical than farnesyl-pyrophosphate in glial cells.

252 or geranylgeranyl-pyrophosphate, but not by farnesyl-pyrophosphate or cholesterol, suggesting that d

253 e to HMG-CoA reductase (upstream enzyme) and farnesyl-pyrophosphate synthase, respectively.

254 ing a palladium catalyzed decarboxylative pi-farnesyl rearrangement of a diketo-dioxinone ester, arom

255 ogy approach, we identify ROD as the Spindly farnesyl receptor.

256 ) ions and the unreactive substrate analogue farnesyl-S-thiolodiphosphate (FSPP), showing that the su

257 Among numerous approaches, nitration of a 3-farnesyl-substituted unprotected pyrrole using AcONO2 ga

258 ing both the porphyrin ring and the hydroxyl farnesyl tail, accompanied by protein movements in nearb

259 lta exhibit a hydrophobic binding pocket for farnesyl, they have different effects on membrane bindin

260 ipid compounds (farnesyl thiosalicylic acid, farnesyl thioacetic acid, 15-deoxy-Delta(12,14)-prostagl

261 ary complex of the rat enzyme incubated with farnesyl thiodiphosphate (FSPP) are reported.

262 drophobic pocket previously reported to bind farnesyl thiodiphosphate (FsPP), as well as biphenyl pho

263 Farnesyl thiodiphosphate competes with substrate ATP to

264 ion conditions; this results in detection of farnesyl thiophosphate (FSP) in the structure of the bin

265 Farnesyl thiosalicylic acid activates the channel in exc

266 ant, we show that the mechanism of action of farnesyl thiosalicylic acid differs from that of the rea

267 ith a potentially novel mechanism of action, farnesyl thiosalicylic acid may be useful in the study o

268 activity, including several lipid compounds (farnesyl thiosalicylic acid, farnesyl thioacetic acid, 1

269 ggest that while Cys181-palmitate and Cys186-farnesyl together provide sufficient hydrophobic force f

270 , interleukin-1beta (IL-1beta), statins, the farnesyl transferase (FT) inhibitor FTI-276 and geranylg

271 used on the development of selective protein farnesyl transferase (FTase) and protein geranylgeranyl

272 Protein farnesyl transferase (FTase) catalyzes transfer of a 15

273 Protein farnesyl transferase (FTase) catalyzes transfer of a 15-

274 rovision of structure-specific inhibitors of farnesyl transferase (FTase; e.g., FTI-277 or FTI-2628)

275 f both geranylgeranyl transferase (GGTI) and farnesyl transferase (FTI) inhibited the activation of N

276 Protein farnesyl transferase (PFTase) is able to site-specifical

277 owed that inhibition of farnesyl-diphosphate farnesyl transferase (squalene synthase), but not 3-hydr

278 5424 on chromosome 8 in farnesyl diphosphate farnesyl transferase 1 (FDFT1) (P = 6.8 x 10(-7)).

279 and squalene synthase (farnesyl diphosphate farnesyl transferase 1)) via novel negative LXR DNA resp

280 of Smad3 results in increased inhibition of farnesyl transferase activity.

281 ploying cell-permeable inhibitors of protein farnesyl transferase and geranylgeranyl transferase enzy

282 rest in their biology and the development of farnesyl transferase and geranylgeranyl transferase inhi

283 ED RESPONSE TO ABA1 (ERA1), that encodes the farnesyl transferase beta-subunit.

284 m oncogenic transformation by (i) augmenting farnesyl transferase inhibition and (ii) suppressing the

285 Inhibition of farnesylation using a farnesyl transferase inhibitor (FTI) abrogated hSpindly

286 le the ortho-substituted isomer was a potent farnesyl transferase inhibitor (FTI) with an inhibition

287 oll onto a single-arm, open-label trial of a farnesyl transferase inhibitor for patients with HRAS mu

288 he mechanism of mTOR activation, we used the farnesyl transferase inhibitor FTI-277, which partially

289 Furthermore, inactivation of Ras by farnesyl transferase inhibitor or K-Ras small interferin

290 not by an inhibitor of farnesyl-transferase (farnesyl transferase inhibitor-277).

291 These data suggest that farnesyl transferase inhibitors should be reevaluated as

292 the presence of a mutant allele of the Cox10 farnesyl transferase involved in heme a biosynthesis or

293 measure the degree of protein prenylation by farnesyl transferase or geranylgeranyl transferase in vi

294 inose synthase, trehalose synthase, amylase, farnesyl transferase, catalase, methyl transferase, lina

295 ion of peptide cosubstrates by yeast protein farnesyl transferase.

296 ihydrochloride)]} but not by an inhibitor of farnesyl-transferase (farnesyl transferase inhibitor-277

297 naling by small interfering RNA (siRNA) or a farnesyl-transferase inhibitor decreases KLF6 SV1 and su

298 Growth inhibition by farnesyl-transferase inhibitor in transformed cell lines

299 ike compounds with 1'-3 linkages between the farnesyl units.

300 le in regulation of nuclear receptors [e.g., farnesyl X receptor (FXR)], leading to enhanced or suppr